Abstract
#Monoclonalantibodies (mAbs) in #oncology are usually administered in
body-size-based or fixed dosing schedules. However, the minor
effects of body size on #distribution and #elimination of mAbs, as well as
a series of practical advantages could support their fixed dosing use. Monoclonal antibodies (mAbs) in oncology are more frequently
administered in body-size-based #dosing schedules as #cytotoxicanticancerdrugs. Simulation studies that compared the performance of
body-size-based and fixed dosing of a series of mAbs in terms of #pharmacokinetic and/or #pharmacodynamic variability demonstrated that the
preferable option could be the fixed dosing for some of them, while
body-size-based dosing for some others [1,2].
For more Biomedical Open Access Journals please click on https://biomedres.us/
For more Research Articles on BJSTR
Pros and Cons of Monoclonal Antibodies Fixed Dosing Administration in Cancer Patients by Alfredo Tartarone in BJSTR
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.